Where does the Paradigm Biopharmaceuticals share price go from here?

Paradigm Biopharmaceuticals Ltd (ASX: PAR): buy, hold, sell?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At the start of April, the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price reached $2.02. Much of Paradigm's share price increase was in anticipation of secondary end point results for its phase 2b osteoarthritis trials.

The recent trial report showed extremely positive results.

Most importantly, it was found that Paradigm's repurposed drug showed a stark difference between itself and the placebo. The results were verified using an MRI scan which measured the lesion caused by bone marrow edema.

At day 53 of treatment, Paradigm's repurposed drug showed a reduced bone marrow lesion volume of 34% vs the placebos 3.6%. Furthermore, the bone marrow lesion area increased in the placebo group by 11.9% compared to a 25.3% decrease in the treatment group.

The objective results obtained were also statistically significant with a p-value of 0.03, meaning that it's highly likely that Paradigm's repurposed drug is causing the improvement of bone marrow lesions.

Why did the Paradigm share price not respond accordingly?

Despite fantastic secondary endpoint results from Paradigm, the share price did not react positively.

The cause can be attributed to Paradigm's capital raise at a significant discount which was announced alongside the secondary endpoint results.

Although Paradigm's share price could have responded better, Paradigm received strong attention for its $77.9 million capital raise which should be filled promptly.

Paradigm expects a cash level of $82 million post raise which will allow it to take its repurposed drug through phase 3 trials.

Additionally, a strong cash position by Paradigm will ensure a better offer from potential future negotiators.

At this stage, Paradigm is aware that it has a potential blockbuster drug on its hands and therefore wouldn't give it up without a significant premium.

Where does Paradigm go from here?

Paradigm has multiple share price catalysts coming up. These include the phase 2/3 clinical trials for MPS and the approval for selling its repurposed drug in Australia.

With the results obtained from its phase 2b trials, Paradigm has significantly de-risked its repurposed drug for phase 3.

Foolish takeaway 

Paradigm Biopharmaceuticals is currently well positioned to take its repurposed drug into phase 3 clinical trials. If Paradigm succeeds throughout phase 3, the share price could take off for many years to come.

For other growth companies, be sure to check out…

Motley Fool contributor Elton Wang owns shares of PARADIGM BIO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to bank a small rise this Tuesday.

Read more »

Sport trainer talking to little girl who is climbing wooden ladder in gym.
Share Gainers

Why Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today

These shares are gaining on Tuesday, but why?

Read more »

A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.
Share Market News

ASX 200 slides on unexpected RBA interest rate call

The ASX 200 is tumbling on the RBA’s latest interest rate announcement.

Read more »

A young woman smiles as she rides a zip line high above the trees.
Financial Shares

5 best ASX 200 financial shares of FY25 (CBA didn't make the cut!)

These stocks were well and truly 'in the black' for share price growth last financial year.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Beetaloo, Botanix, Cobram Estate, and Origin Energy shares are falling today

These shares are having a poor session on Tuesday. But why?

Read more »

Two parents and two children happily eat pizza in their kitchen.
Broker Notes

Morgans reveals 4 ASX All Ords shares to buy now — and 2 may surprise you

The top broker has revealed a buy rating on four ASX All Ords shares from different market sectors.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Amaero, Black Cat, Domino's, and Ramelius shares are racing higher today

These shares are having a good session on Tuesday. But why?

Read more »

Five happy miners standing next to each other representing ASX coal mining shares which some brokers say could pay big dividends this year
Broker Notes

Macquarie predicts 63% upside for this ASX 200 mining stock

Which ASX 200 stock is it?

Read more »